Hemab

Hemab is a Copenhagen-based biotech company founded in 2019, focused on developing treatments for rare bleeding and thrombotic disorders. The company has a pipeline of five drug candidates, including HMB-001, targeting distinct bleeding disorders.

Investment rationale 

Hemab provides exposure to innovation in rare bleeding and thrombotic disorders, where patient needs remain significant. Its development platform and drug pipeline position the company to benefit from progress and demand for effective, targeted therapies.

Headquarters: Copenhagen, Denmark

Website: https://www.hemab.com/ 

Responsible partner: Jannick Mortensen

Fund: MIM II